Burkitt lymphoma is a highly aggressive B-cell non-Hodgkin lymphoma characterized by MYC oncogene translocation, typically t(8;14)(q24;q32) involving the immunoglobulin heavy chain locus. Three clinical variants exist: endemic (African), sporadic, and immunodeficiency-associated. Endemic Burkitt lymphoma is strongly associated with Epstein-Barr virus (EBV) infection and commonly presents as jaw tumors in children in malaria-endemic regions. The disease exemplifies the role of MYC dysregulation in driving uncontrolled cell proliferation, with one of the fastest doubling times of any human cancer.
Ask a research question about Burkitt Lymphoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Burkitt Lymphoma
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-05-08T18:54:20Z'
description: >-
Burkitt lymphoma is a highly aggressive B-cell non-Hodgkin lymphoma characterized
by MYC oncogene translocation, typically t(8;14)(q24;q32) involving the immunoglobulin
heavy chain locus. Three clinical variants exist: endemic (African), sporadic, and
immunodeficiency-associated. Endemic Burkitt lymphoma is strongly associated with
Epstein-Barr virus (EBV) infection and commonly presents as jaw tumors in children
in malaria-endemic regions. The disease exemplifies the role of MYC dysregulation
in driving uncontrolled cell proliferation, with one of the fastest doubling times
of any human cancer.
categories:
- Hematologic Malignancy
- B-Cell Lymphoma
- Virus-Associated Cancer
parents:
- non-Hodgkin lymphoma
has_subtypes:
- name: Endemic Burkitt Lymphoma
description: >-
African variant strongly associated with EBV infection (>95% EBV-positive),
occurring predominantly in children in equatorial Africa. Classically presents
as jaw or facial tumors. Geographic distribution correlates with malaria
endemicity, suggesting chronic immune activation as a cofactor.
- name: Sporadic Burkitt Lymphoma
description: >-
Occurs worldwide without geographic restriction. Less commonly EBV-associated
(15-30% in developed countries). Typically presents with abdominal masses,
often involving the ileocecal region. More common in children and young adults.
- name: Immunodeficiency-Associated Burkitt Lymphoma
description: >-
Occurs in patients with HIV/AIDS or other immunodeficiency states. EBV
association is intermediate (25-40%). May present as the initial AIDS-defining
illness. Requires concurrent management of underlying immunodeficiency.
infectious_agent:
- name: Epstein-Barr Virus (EBV)
infectious_agent_term:
preferred_term: Human gammaherpesvirus 4
term:
id: NCBITaxon:10376
label: Human gammaherpesvirus 4
description: >-
EBV infection is nearly universal in endemic Burkitt lymphoma (>95%) but
variable in sporadic (15-30%) and immunodeficiency-associated (25-40%) forms.
EBV provides survival signals through EBNA1 and contributes to genomic instability,
but MYC translocation is the essential oncogenic driver. EBV latency type I is
typically observed with expression of EBNA1 and EBERs only.
evidence:
- reference: PMID:7797201
reference_title: "A study of the association of Epstein-Barr virus with Burkitt's lymphoma occurring in a Chinese population."
supports: SUPPORT
snippet: "There is a strong association (approximately 95%) of endemic Burkitt's lymphoma with Epstein-Barr virus (EBV)"
explanation: "Abstract reports high EBV association in endemic Burkitt lymphoma."
pathophysiology:
- name: MYC Translocation and Oncogene Activation
description: >-
The hallmark of Burkitt lymphoma is translocation of the MYC oncogene on
chromosome 8 to an immunoglobulin locus, most commonly t(8;14)(q24;q32)
involving the IGH locus, or less commonly t(2;8) or t(8;22) involving
light chain loci. This places MYC under control of immunoglobulin enhancers,
resulting in constitutive MYC overexpression.
evidence:
- reference: PMID:40893393
reference_title: "Navigating Rare Presentations: Recurrent Burkitt Lymphoma Presenting as a Jejunal Mass."
supports: SUPPORT
snippet: "Burkitt lymphoma (BL) is an aggressive B-cell malignancy characterized by rapid progression and MYC gene translocations."
explanation: This abstract directly identifies MYC translocations as a defining feature of Burkitt lymphoma.
- reference: PMID:1301171
reference_title: "Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb."
supports: SUPPORT
snippet: "In about 80% of Burkitt's lymphoma cases, the tumour cell harbours a reciprocal chromosomal translocation which invariably transposes the coding exons 2 and 3 of c-myc from chromosome 8 to the immunoglobulin heavy chain locus on chromosome 14."
explanation: "Abstract reports MYC translocation to immunoglobulin loci in most Burkitt lymphoma cases."
cell_types:
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
biological_processes:
- preferred_term: positive regulation of transcription by RNA polymerase II
modifier: INCREASED
term:
id: GO:0045944
label: positive regulation of transcription by RNA polymerase II
downstream:
- target: Uncontrolled B-Cell Proliferation
description: MYC drives cell cycle entry and proliferation
- target: Apoptosis Resistance
description: MYC cooperates with anti-apoptotic signals to enable tumor cell survival
- name: Uncontrolled B-Cell Proliferation
description: >-
MYC is a master transcriptional regulator of cell growth and proliferation.
Constitutive MYC expression drives continuous cell cycle progression, resulting
in one of the fastest doubling times of any human tumor (approximately 24 hours).
The proliferation fraction approaches 100% (Ki-67 staining).
cell_types:
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
downstream:
- target: High-Grade Malignancy with Rapid Tumor Growth
description: Extremely rapid proliferation leads to aggressive clinical behavior
- name: Apoptosis Resistance
description: >-
While MYC normally sensitizes cells to apoptosis, Burkitt lymphoma cells
acquire mutations or alterations that counteract MYC-induced apoptosis.
TP53 mutations occur in approximately 30% of cases. EBV-encoded EBNA1 and
EBERs provide additional survival signals in EBV-positive cases.
biological_processes:
- preferred_term: apoptotic process
modifier: DECREASED
term:
id: GO:0006915
label: apoptotic process
- name: High-Grade Malignancy with Rapid Tumor Growth
description: >-
The combination of constitutive MYC-driven proliferation and apoptosis
resistance results in rapidly growing tumors. The high proliferation rate
paradoxically makes the tumor highly sensitive to chemotherapy, contributing
to excellent cure rates with intensive treatment.
evidence:
- reference: PMID:40893393
reference_title: "Navigating Rare Presentations: Recurrent Burkitt Lymphoma Presenting as a Jejunal Mass."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Burkitt lymphoma (BL) is an aggressive B-cell malignancy characterized by rapid progression and MYC gene translocations."
explanation: Abstract characterizes BL as rapidly progressive, supporting the high-grade, rapid-growth phenotype of this pathophysiology node.
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
histopathology:
- name: Aggressive B-Cell Lymphoma
finding_term:
preferred_term: Aggressive B-Cell Non-Hodgkin Lymphoma
term:
id: NCIT:C178541
label: Aggressive B-Cell Non-Hodgkin Lymphoma
frequency: VERY_FREQUENT
description: Burkitt lymphoma is an aggressive form of B cell lymphoma.
evidence:
- reference: PMID:36522349
reference_title: "Burkitt lymphoma."
supports: SUPPORT
snippet: "Burkitt lymphoma (BL) is an aggressive form of B cell lymphoma that can affect"
explanation: Abstract describes Burkitt lymphoma as an aggressive B-cell lymphoma.
phenotypes:
- category: Abdominal
name: Abdominal Mass
frequency: VERY_FREQUENT
description: >-
Rapidly enlarging abdominal mass, typically ileocecal, is the most common
presentation in sporadic Burkitt lymphoma. May cause bowel obstruction or
intussusception.
phenotype_term:
preferred_term: Abdominal distention
term:
id: HP:0003270
label: Abdominal distention
- category: Head and Neck
name: Jaw Mass
frequency: FREQUENT
description: >-
Characteristic presentation in endemic Burkitt lymphoma. Rapidly growing
jaw or facial tumors, often involving the mandible or maxilla with dental
abnormalities.
phenotype_term:
preferred_term: Abnormal mandible morphology
term:
id: HP:0000277
label: Abnormal mandible morphology
- category: Lymphatic
name: Lymphadenopathy
frequency: FREQUENT
description: >-
Bulky lymphadenopathy with rapid growth. May involve multiple nodal sites.
phenotype_term:
preferred_term: Lymphadenopathy
term:
id: HP:0002716
label: Lymphadenopathy
- category: Constitutional
name: Weight Loss
frequency: FREQUENT
description: >-
Rapid weight loss due to high metabolic demands of rapidly proliferating tumor.
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
- category: Constitutional
name: Fatigue
frequency: FREQUENT
description: >-
Profound fatigue related to tumor burden and metabolic effects.
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
- category: Abdominal
name: Hepatomegaly
frequency: OCCASIONAL
description: >-
Liver involvement may occur with advanced disease.
phenotype_term:
preferred_term: Hepatomegaly
term:
id: HP:0002240
label: Hepatomegaly
- category: Abdominal
name: Splenomegaly
frequency: OCCASIONAL
description: >-
Splenic involvement may occur, particularly in advanced disease.
phenotype_term:
preferred_term: Splenomegaly
term:
id: HP:0001744
label: Splenomegaly
biochemical:
- name: Elevated Lactate Dehydrogenase (LDH)
notes: >-
LDH is markedly elevated reflecting high tumor cell turnover. Serves as
important prognostic marker and indicator of tumor burden.
- name: Uric Acid Elevation
notes: >-
Hyperuricemia from rapid cell turnover. Risk of tumor lysis syndrome is
high and requires prophylaxis with allopurinol or rasburicase.
genetic:
- name: MYC
association: Somatic Translocation
notes: >-
MYC translocation to immunoglobulin loci is the defining genetic abnormality.
t(8;14)(q24;q32) involving IGH occurs in ~80% of cases. t(2;8) involving
IGK and t(8;22) involving IGL occur in the remainder. MYC overexpression
drives the malignant phenotype.
- name: TP53
association: Somatic Mutation
notes: >-
TP53 mutations occur in approximately 30% of cases and confer worse prognosis.
Loss of p53 function contributes to apoptosis resistance and genomic instability.
- name: ID3
association: Somatic Mutation
notes: >-
ID3 mutations occur in approximately 40-70% of cases and promote B-cell
receptor signaling and cell survival.
- name: TCF3
association: Somatic Mutation
notes: >-
TCF3 (E2A) mutations occur in approximately 10-25% of cases and cooperate
with ID3 mutations to promote B-cell receptor signaling.
diagnosis:
- name: Morphology and MYC-centered diagnostic confirmation
description: >-
Burkitt lymphoma diagnosis integrates tumor morphology, MYC expression or
rearrangement, and B-cell immunophenotyping; extranodal cases still require
tissue confirmation with lymphoma markers.
diagnosis_term:
preferred_term: clinical assessment
term:
id: MAXO:0000487
label: clinical assessment
results: High-grade B-cell lymphoma morphology with high MYC expression and/or MYC translocation.
evidence:
- reference: PMID:36522349
reference_title: "Burkitt lymphoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "BL is diagnosed on the basis of morphology and high expression of MYC."
explanation: The disease primer summarizes morphology and MYC expression as core diagnostic criteria.
- reference: PMID:40893393
reference_title: "Navigating Rare Presentations: Recurrent Burkitt Lymphoma Presenting as a Jejunal Mass."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Push enteroscopy with biopsy confirmed the recurrence of BL in the jejunum, with positive markers for CD45, CD20, BCL6, and c-Myc."
explanation: This case illustrates tissue confirmation with B-cell and MYC immunophenotypic markers.
treatments:
- name: Intensive Chemotherapy
description: >-
Intensive, short-duration chemotherapy regimens achieve high cure rates
(>90% in children, 60-80% in adults). Regimens include CODOX-M/IVAC,
hyper-CVAD, and DA-EPOCH-R. CNS prophylaxis is essential given high
risk of CNS involvement.
evidence:
- reference: PMID:36522349
reference_title: "Burkitt lymphoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "BL can be effectively treated in children and adolescents with short durations of high dose-intensity multiagent chemotherapy regimens."
explanation: Nature Reviews Disease Primers directly supports intensive, short-duration, high-dose chemotherapy as the standard-of-care for pediatric BL.
treatment_term:
preferred_term: chemotherapy
term:
id: MAXO:0000647
label: chemotherapy
- name: Rituximab
description: >-
Anti-CD20 monoclonal antibody added to chemotherapy improves outcomes,
particularly in adults. Standard component of modern treatment regimens.
treatment_term:
preferred_term: immunotherapy
term:
id: NCIT:C15262
label: Immunotherapy
therapeutic_agent:
- preferred_term: rituximab
term:
id: NCIT:C1702
label: Rituximab
- name: Tumor Lysis Syndrome Prophylaxis
description: >-
Aggressive hydration, allopurinol or rasburicase, and electrolyte monitoring
are essential given the extremely high risk of tumor lysis syndrome from
rapid tumor cell death.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
therapeutic_agent:
- preferred_term: allopurinol
term:
id: NCIT:C224
label: Allopurinol
- preferred_term: rasburicase
term:
id: NCIT:C2404
label: Rasburicase
disease_term:
preferred_term: Burkitt lymphoma
term:
id: MONDO:0007243
label: Burkitt lymphoma
classifications:
icdo_morphology:
classification_value: Lymphoma
harrisons_chapter:
- classification_value: cancer
- classification_value: hematologic malignancy
references:
- reference: DOI:10.1002/ijc.34618
title: Incidence of Burkitt lymphoma in the United States during 2000 to 2019
found_in:
- Burkitt_Lymphoma-deep-research-falcon.md
findings:
- statement: Burkitt lymphoma (BL) is an aggressive B‐cell lymphoma that occurs worldwide.
supporting_text: Burkitt lymphoma (BL) is an aggressive B‐cell lymphoma that occurs worldwide.
evidence:
- reference: DOI:10.1002/ijc.34618
reference_title: Incidence of Burkitt lymphoma in the United States during 2000 to 2019
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Burkitt lymphoma (BL) is an aggressive B‐cell lymphoma that occurs worldwide.
explanation: Deep research cited this publication as relevant literature for Burkitt Lymphoma.
- reference: DOI:10.1002/path.6246
title: 'The fifth edition of the WHO classification of mature B‐cell neoplasms: open questions for research'
found_in:
- Burkitt_Lymphoma-deep-research-falcon.md
findings:
- statement: The fifth edition of the World Health Organization Classification of Haematolymphoid Tumours (WHO‐HAEM5) is the product of an evidence‐based evolution of the revised fourth edition with wide multidisciplinary consultation.
supporting_text: The fifth edition of the World Health Organization Classification of Haematolymphoid Tumours (WHO‐HAEM5) is the product of an evidence‐based evolution of the revised fourth edition with wide multidisciplinary consultation.
evidence:
- reference: DOI:10.1002/path.6246
reference_title: 'The fifth edition of the WHO classification of mature B‐cell neoplasms: open questions for research'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: The fifth edition of the World Health Organization Classification of Haematolymphoid Tumours (WHO‐HAEM5) is the product of an evidence‐based evolution of the revised fourth edition with wide multidisciplinary consultation.
explanation: Deep research cited this publication as relevant literature for Burkitt Lymphoma.
- reference: DOI:10.1182/blood.2019004099
title: The treatment of Burkitt lymphoma in adults
found_in:
- Burkitt_Lymphoma-deep-research-falcon.md
findings:
- statement: Burkitt lymphoma (BL) is a highly aggressive, B-cell, non-Hodgkin lymphoma categorized into endemic, sporadic, and immunodeficiency-associated subtypes.
supporting_text: Burkitt lymphoma (BL) is a highly aggressive, B-cell, non-Hodgkin lymphoma categorized into endemic, sporadic, and immunodeficiency-associated subtypes.
evidence:
- reference: DOI:10.1182/blood.2019004099
reference_title: The treatment of Burkitt lymphoma in adults
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Burkitt lymphoma (BL) is a highly aggressive, B-cell, non-Hodgkin lymphoma categorized into endemic, sporadic, and immunodeficiency-associated subtypes.
explanation: Deep research cited this publication as relevant literature for Burkitt Lymphoma.
- reference: DOI:10.26508/lsa.202101355
title: Endemic Burkitt lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies
found_in:
- Burkitt_Lymphoma-deep-research-falcon.md
findings:
- statement: Endemic Burkitt lymphoma (BL) is a childhood cancer in sub-Saharan Africa characterized by Epstein–Barr virus and malaria-associated aberrant B-cell activation andMYCchromosomal translocation.
supporting_text: Endemic Burkitt lymphoma (BL) is a childhood cancer in sub-Saharan Africa characterized by Epstein–Barr virus and malaria-associated aberrant B-cell activation andMYCchromosomal translocation.
evidence:
- reference: DOI:10.26508/lsa.202101355
reference_title: Endemic Burkitt lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: Endemic Burkitt lymphoma (BL) is a childhood cancer in sub-Saharan Africa characterized by Epstein–Barr virus and malaria-associated aberrant B-cell activation andMYCchromosomal translocation.
explanation: Deep research cited this publication as relevant literature for Burkitt Lymphoma.
- reference: DOI:10.3390/diagnostics13122068
title: 'Worldwide Prevalence of Epstein–Barr Virus in Patients with Burkitt Lymphoma: A Systematic Review and Meta-Analysis'
found_in:
- Burkitt_Lymphoma-deep-research-falcon.md
findings:
- statement: Burkitt lymphoma (BL) is a form of B-cell malignancy that progresses aggressively and is most often seen in children.
supporting_text: Burkitt lymphoma (BL) is a form of B-cell malignancy that progresses aggressively and is most often seen in children.
evidence:
- reference: DOI:10.3390/diagnostics13122068
reference_title: 'Worldwide Prevalence of Epstein–Barr Virus in Patients with Burkitt Lymphoma: A Systematic Review and Meta-Analysis'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Burkitt lymphoma (BL) is a form of B-cell malignancy that progresses aggressively and is most often seen in children.
explanation: Deep research cited this publication as relevant literature for Burkitt Lymphoma.
- reference: DOI:10.3390/ijms252313213
title: A Diagnostic Approach in Large B-Cell Lymphomas According to the Fifth World Health Organization and International Consensus Classifications and a Practical Algorithm in Routine Practice
found_in:
- Burkitt_Lymphoma-deep-research-falcon.md
findings:
- statement: In this article, we provide a review of large B-cell lymphomas (LBCLs), comparing the recently published fifth edition of the WHO classification and the International Consensus Classification (ICC) on hematolymphoid tumors.
supporting_text: In this article, we provide a review of large B-cell lymphomas (LBCLs), comparing the recently published fifth edition of the WHO classification and the International Consensus Classification (ICC) on hematolymphoid tumors.
evidence:
- reference: DOI:10.3390/ijms252313213
reference_title: A Diagnostic Approach in Large B-Cell Lymphomas According to the Fifth World Health Organization and International Consensus Classifications and a Practical Algorithm in Routine Practice
supports: SUPPORT
evidence_source: OTHER
snippet: In this article, we provide a review of large B-cell lymphomas (LBCLs), comparing the recently published fifth edition of the WHO classification and the International Consensus Classification (ICC) on hematolymphoid tumors.
explanation: Deep research cited this publication as relevant literature for Burkitt Lymphoma.
- reference: DOI:10.3390/lymphatics1020010
title: 'Translocation Tales: Unraveling the MYC Deregulation in Burkitt Lymphoma for Innovative Therapeutic Strategies'
found_in:
- Burkitt_Lymphoma-deep-research-falcon.md
findings:
- statement: MYC deregulation, a cardinal event in Burkitt lymphoma (BL) pathogenesis, necessitates the elucidation of the molecular mechanisms governing MYC activation to devise innovative and effective therapeutic strategies.
supporting_text: MYC deregulation, a cardinal event in Burkitt lymphoma (BL) pathogenesis, necessitates the elucidation of the molecular mechanisms governing MYC activation to devise innovative and effective therapeutic strategies.
evidence:
- reference: DOI:10.3390/lymphatics1020010
reference_title: 'Translocation Tales: Unraveling the MYC Deregulation in Burkitt Lymphoma for Innovative Therapeutic Strategies'
supports: SUPPORT
evidence_source: OTHER
snippet: MYC deregulation, a cardinal event in Burkitt lymphoma (BL) pathogenesis, necessitates the elucidation of the molecular mechanisms governing MYC activation to devise innovative and effective therapeutic strategies.
explanation: Deep research cited this publication as relevant literature for Burkitt Lymphoma.
Burkitt lymphoma is a highly aggressive mature B-cell lymphoma characterized by rapid tumor growth, frequent extranodal disease, and a defining genomic hallmark of MYC dysregulation due to IG::MYC translocation. (crombie2021thetreatmentof pages 3-4, zanelli2024adiagnosticapproach pages 6-8)
BL is classically described in three variants: endemic, sporadic, and immunodeficiency-associated. (zanelli2024adiagnosticapproach pages 6-8, malfona2024refractoryburkittlymphoma pages 1-2)
Direct abstract quote (definition): Crombie & LaCasce (Blood, 2021) define BL as “a highly aggressive, B-cell, non-Hodgkin lymphoma (NHL) categorized into endemic, sporadic and immunodeficiency-associated subtypes.” (crombie2021thetreatmentof pages 1-2)
Recent diagnostic reviews emphasize alignment of daily practice with WHO 5th edition (WHO-HAEM5) and the International Consensus Classification (ICC, 2022), including new/clarified boundaries between BL, HGBL-NOS, and MYC-negative BL mimics. (zanelli2024adiagnosticapproach pages 6-8, zanelli2024adiagnosticapproach pages 9-11, coupland2024thefifthedition pages 12-12)
Genetic driver: The central causal lesion is MYC activation via an immunoglobulin locus–MYC translocation (most commonly IGH::MYC). (malfona2024refractoryburkittlymphoma pages 1-2, zanelli2024adiagnosticapproach pages 6-8)
Infectious cofactor: Epstein–Barr virus (EBV) contributes strongly in endemic BL and in subsets of other variants. A 2023 meta-analysis estimated EBV presence in 57.5% of BL patients overall (pooled worldwide). (alkhreisat2023worldwideprevalenceof pages 1-2)
Direct abstract quote (EBV prevalence meta-analysis): Al‑Khreisat et al. (Diagnostics, 2023) report: “The prevalence of Epstein–Barr virus in patients with Burkitt lymphoma was 57.5% (95% CI: 51.5 to 63.4, n = 4837).” (alkhreisat2023worldwideprevalenceof pages 1-2)
Geographic/ecologic: Endemic BL is described as occurring in malaria-endemic regions and being largely EBV-driven; the SSA burden is substantial and strongly linked to diagnostic and treatment capacity constraints. (chamba2023clinicalapplicationof pages 1-2, chamba2023clinicalapplicationof pages 2-3)
Immunodeficiency: Immunodeficiency-associated BL includes HIV-associated BL; EBV positivity in sporadic/immunodeficiency-associated BL is reported in the ~25–40% range by a high-impact treatment review. (crombie2021thetreatmentof pages 3-4)
No specific genetic protective variants or environmental protective factors were identified in the retrieved sources for this run; this remains a gap for the knowledge-base entry requiring targeted searches (e.g., GWAS Catalog, host genetic studies of EBV/malaria interaction).
The retrieved 2023–2024 sources support a conceptual interaction where chronic immune stimulation/infection exposure (EBV; malaria in endemic regions; immunodeficiency states) increases the probability of transformation in a B cell already prone to/experiencing MYC dysregulation, but they do not provide quantitative interaction effect sizes in the accessible excerpts. (chamba2023clinicalapplicationof pages 1-2, malfona2024refractoryburkittlymphoma pages 1-2)
BL is a rapidly progressive lymphoma with frequent extranodal involvement; endemic cases commonly involve craniofacial/jaw regions, while sporadic cases often present with abdominal disease (pattern-level statements supported in diagnostic and clinical reviews). (harlendea2024ki67asa pages 2-4, crombie2021thetreatmentof pages 3-4)
The diagnostic phenotype strongly shapes “phenotype” documentation: - Morphology: diffuse proliferation of relatively uniform medium-sized cells with frequent mitoses and a “starry sky” pattern. (zanelli2024adiagnosticapproach pages 6-8) - Immunophenotype: germinal center profile with CD10+, BCL6+, typically BCL2−/weak, and very high proliferation (Ki-67 typically >95%). (zanelli2024adiagnosticapproach pages 6-8, malfona2024refractoryburkittlymphoma pages 1-2)
Because the retrieved excerpts emphasize diagnostic morphology and general clinical aggressiveness rather than structured symptom prevalence, the most defensible HPO mapping in this run is to lymphoma-related and organ-mass manifestations and laboratory/complication phenotypes described in BL treatment contexts: - Lymphadenopathy (HP:0002716) (supported as a common presenting feature in adult/adolescent cohort description) (harlendea2024ki67asa pages 2-4) - Abdominal pain (HP:0002027) (harlendea2024ki67asa pages 2-4) - Tumor lysis syndrome (HP:0003466) (not quantified in retrieved evidence excerpts; included as clinically relevant but requires primary citation beyond current excerpts)
Gap note: The template requests onset/progression/frequency/QoL per phenotype; these require dedicated cohort and QoL instrument papers that were not retrieved in this run.
Reported translocation partners and approximate frequencies: - t(8;14) IGH::MYC: ~70–80% (siddiqui2023fromthearchives pages 3-4) - t(2;8) IGK::MYC: ~15% (siddiqui2023fromthearchives pages 3-4) - t(8;22) IGL::MYC: ~5% (siddiqui2023fromthearchives pages 3-4)
Multiple sources emphasize cooperating lesions, particularly in BCR/PI3K signaling and cell-cycle control: - TCF3 / ID3 pathway: reported as mutated in ~70% of sporadic and immunodeficiency-associated BL and ~40% of endemic BL in a diagnostic pathology review; this pathway connects to PI3K and CCND3 activation. (siddiqui2023fromthearchives pages 3-4) - CCND3: reported as found in about one-third of cases in a 2024 clinical review. (malfona2024refractoryburkittlymphoma pages 1-2) - TP53: TP53 alterations occur in BL (e.g., up to ~35% reported in an adult BL treatment review excerpt). (crombie2021thetreatmentof pages 3-4)
EBV detection is typically via EBER in situ hybridization and is linked to distinct latency programs; EBER1/2 are noted as markers of EBV infection in BL. (zanelli2024adiagnosticapproach pages 6-8, siddiqui2023fromthearchives pages 3-4)
Based on described biology (MYC-driven proliferation; apoptosis evasion; metabolic reprogramming), plausible GO terms for knowledge-base scaffolding include: - Cell cycle process (GO:0022402) - Regulation of apoptotic process (GO:0042981) - Regulation of B cell activation (GO:0050864) These are mechanistically consistent with the MYC-centric and apoptosis/IFN signatures described in models and reviews, but the retrieved excerpts do not provide explicit GO mappings. (tandon2023translocationtalesunraveling pages 16-17, lakshmi2023endemicburkittlymphoma pages 10-12)
In sub-Saharan Africa, non-biologic environmental/system factors materially influence outcomes, particularly limited access to reliable diagnostic services, which contributes to delay and misdiagnosis. (chamba2023clinicalapplicationof pages 1-2)
Direct quote (diagnostic access/outcomes context): Chamba et al. (Cambridge Prisms: Precision Medicine, 2023) report “limited access to reliable diagnostic services leading to significant delays and misdiagnoses.” (chamba2023clinicalapplicationof pages 1-2)
Model-informed heterogeneity and response biology: Patient-derived BL “avatar” mouse models (NSG-BL) show substantial inter-patient heterogeneity in growth/survival and EBV protein expression and reveal distinct signatures of rituximab sensitivity (apoptosis/mTORC1) vs unresponsiveness (IFN-α signature involving IRF7/ISG15). (lakshmi2023endemicburkittlymphoma pages 1-2, lakshmi2023endemicburkittlymphoma pages 10-12)
BL is a germinal center B-cell phenotype lymphoma (CD10+, BCL6+) and expresses mature B-cell markers (CD20, CD79a, PAX5, CD19, surface IgM). (zanelli2024adiagnosticapproach pages 6-8, crombie2021thetreatmentof pages 3-4)
BL is described as a rapidly progressive neoplasm, and endemic BL peaks in childhood (median age ~6 years in review background). (alkhreisat2023worldwideprevalenceof pages 2-3, malfona2024refractoryburkittlymphoma pages 1-2)
Mburu et al. analyzed 11,626 BL cases in SEER 22 (2000–2019) and reported: - Age-standardized incidence: 3.96 per million person-years (mburu2023incidenceofburkitt pages 1-3) - Sex ratio: 2.85:1 male:female (mburu2023incidenceofburkitt pages 1-3) - 2-year overall survival: 64%, with improvement over time (“Survival improved by 20% between 2000 and 2019.”) (mburu2023incidenceofburkitt pages 1-3)
Direct abstract quote (incidence/survival): Mburu et al. (Int J Cancer, 2023) report “The age-standardized BL incidence rate was 3.96/million person-years, with a 2.85:1 male-to-female ratio” and “Overall survival from BL was 64% at 2 years.” (mburu2023incidenceofburkitt pages 1-3)
Chamba et al. summarize large heterogeneity in SSA incidence and high mortality: - Incidence range: 0.5/million (Ethiopia) to 19.3/million (Malawi) (chamba2023clinicalapplicationof pages 1-2) - Estimated new cases: ~3,900 in SSA in 2018 (chamba2023clinicalapplicationof pages 1-2) - Outcome: “more than 50%” of children/young adults with endemic BL in SSA do not survive (chamba2023clinicalapplicationof pages 1-2)
Diagnosis relies on typical morphology, germinal-center B-cell immunophenotype, and confirmation of the isolated IG::MYC rearrangement, with routine assessment of EBV status by EBER in situ hybridization (especially for classification and context). (zanelli2024adiagnosticapproach pages 6-8, zanelli2024adiagnosticapproach pages 9-11)
Commonly emphasized IHC pattern: - B-cell markers: CD20, CD79a, PAX5, CD19 (zanelli2024adiagnosticapproach pages 6-8) - Germinal center markers: CD10+, BCL6+ (zanelli2024adiagnosticapproach pages 6-8) - BCL2 negative or weak (zanelli2024adiagnosticapproach pages 6-8) - Ki-67 typically >95% (zanelli2024adiagnosticapproach pages 6-8, malfona2024refractoryburkittlymphoma pages 1-2)
A WHO/ICC-oriented diagnostic review recommends EBER in situ hybridization and reports EBER positivity in most endemic BL and ~30% of sporadic/immunodeficiency-associated BL. (zanelli2024adiagnosticapproach pages 6-8)
A 2023 precision-medicine review proposes circulating tumor DNA (ctDNA)/cell-free DNA (cfDNA) approaches to improve diagnosis and monitoring in SSA where FISH/PET may be limited: - “c-MYC is therefore theoretically an ideal target for the diagnosis of BL from ctDNA.” (chamba2023clinicalapplicationof pages 1-2) - Sequencing of plasma ctDNA detected MYC translocations in ~79% of cases vs FISH, rising to ~95% in high tumor burden (ctDNA >16 pg/ml). (chamba2023clinicalapplicationof pages 3-4) - Implementation barriers: limited pathology capacity, lack of accredited labs, limited bioinformatics training/infrastructure, and long tissue-diagnostic delays (up to 71 days vs 2 days in the USA). (chamba2023clinicalapplicationof pages 2-3, chamba2023clinicalapplicationof pages 4-5)
Two-year overall survival was 64% in SEER 2000–2019 analysis, with highest survival in pediatric patients and lowest in Black and elderly individuals. (mburu2023incidenceofburkitt pages 1-3)
A 2024 review emphasizes that despite high frontline cure rates, refractory BL has very poor outcomes.
Direct abstract quote (refractory outcomes): Malfona et al. (Blood and Lymphatic Cancer: Targets and Therapy, published March 2024) state: “The prognosis is very poor, ranging from less than 10% to 30–40%, with longer survival only in transplanted patients.” (malfona2024refractoryburkittlymphoma pages 1-2)
Frontline therapy is based on intensive, multi-agent chemotherapy regimens, often with anti-CD20 immunotherapy (rituximab); outcomes are generally excellent in pediatric populations and lower in adults, with major challenges in refractory disease. (malfona2024refractoryburkittlymphoma pages 1-2, harlendea2024ki67asa pages 2-4)
A 2024 refractory BL review summarizes frontline outcome expectations: - Cure rates “outreaching 90%” in pediatric age and “70%” in adult age in settings with standard intensive approaches. (malfona2024refractoryburkittlymphoma pages 1-2)
A 2024 refractory BL review notes emerging targeted strategies across multiple axes (e.g., BCR pathway inhibitors, proteasome inhibitors, next-generation antibodies, CAR-T and bispecific antibodies) but emphasizes limited data and heterogeneity of salvage settings. (malfona2024refractoryburkittlymphoma pages 1-2)
ClinicalTrials.gov search retrieved multiple recruiting/active CAR-T trials broadly enrolling relapsed/refractory B-cell hematologic malignancies that may include BL among eligible B-cell lymphomas, e.g.: - NCT06735495 (CD19 & CD22 bispecific CAR-T; Phase 1/2; recruiting) (NCT06735495 chunk 1, NCT06735495 chunk 2) - NCT06503094 (CD19 & CD20 bispecific CAR-T; Phase 1/2; recruiting) (NCT06503094 chunk 1, NCT06503094 chunk 2)
Note: Eligibility specifics for Burkitt lymphoma require per-trial confirmation from the full record text.
No BL-specific primary prevention interventions were directly evidenced in the retrieved excerpts beyond the general implication that reducing infection-related drivers (EBV/malaria) and improving HIV management could reduce risk. The 2023–2024 retrieved sources focus more on diagnostic and treatment capacity as the most immediate, actionable lever for mortality reduction in endemic settings. (chamba2023clinicalapplicationof pages 1-2, chamba2023clinicalapplicationof pages 4-5)
No naturally occurring non-human BL analogs were identified in the retrieved evidence excerpts. (Gap for targeted veterinary/OMIA searches.)
Lakshmi et al. (Life Science Alliance, 2023) established five patient-derived BL tumor cell lines and corresponding NSG-BL avatar mouse models, demonstrating transcriptomic fidelity to the originating tumors and substantial inter-patient heterogeneity in growth/survival and EBV protein expression. (lakshmi2023endemicburkittlymphoma pages 1-2)
These models were used to test rituximab response and to identify response-associated pathways (apoptosis/mTORC1 vs IFN-α signatures), providing a translational framework for prioritizing targeted therapies relevant to endemic BL. (lakshmi2023endemicburkittlymphoma pages 10-12)
Many retrieved sources were provided with DOIs/URLs but not PMIDs in the tool outputs. Where PMIDs are required for the knowledge base, these should be added by matching DOI→PMID in PubMed during curation. This limitation reflects metadata availability in the retrieved excerpts rather than absence of PubMed indexing.
References
(zanelli2024adiagnosticapproach pages 6-8): Magda Zanelli, Francesca Sanguedolce, Maurizio Zizzo, Stefano Ricci, Alessandra Bisagni, Andrea Palicelli, Valentina Fragliasso, Benedetta Donati, Giuseppe Broggi, Ioannis Boutas, Nektarios Koufopoulos, Moira Foroni, Francesca Coppa, Andrea Morini, Paola Parente, Valeria Zuccalà, Rosario Caltabiano, Massimiliano Fabozzi, Luca Cimino, Antonino Neri, and Stefano Ascani. A diagnostic approach in large b-cell lymphomas according to the fifth world health organization and international consensus classifications and a practical algorithm in routine practice. International Journal of Molecular Sciences, 25:13213, Dec 2024. URL: https://doi.org/10.3390/ijms252313213, doi:10.3390/ijms252313213. This article has 10 citations.
(crombie2021thetreatmentof pages 3-4): Jennifer Crombie and Ann LaCasce. The treatment of burkitt lymphoma in adults. Blood, 137:743-750, Feb 2021. URL: https://doi.org/10.1182/blood.2019004099, doi:10.1182/blood.2019004099. This article has 160 citations and is from a highest quality peer-reviewed journal.
(mburu2023incidenceofburkitt pages 1-3): Waruiru Mburu, Susan S. Devesa, David Check, Meredith S. Shiels, and Sam M. Mbulaiteye. Incidence of burkitt lymphoma in the united states during 2000 to 2019. International Journal of Cancer, 153:1182-1191, Jun 2023. URL: https://doi.org/10.1002/ijc.34618, doi:10.1002/ijc.34618. This article has 18 citations and is from a domain leading peer-reviewed journal.
(alkhreisat2023worldwideprevalenceof pages 1-2): Mutaz Jamal Al-Khreisat, Nor Hayati Ismail, Abedelmalek Tabnjh, Faezahtul Arbaeyah Hussain, Abdul Aziz Mohamed Yusoff, Muhammad Farid Johan, and Md Asiful Islam. Worldwide prevalence of epstein–barr virus in patients with burkitt lymphoma: a systematic review and meta-analysis. Diagnostics, 13:2068, Jun 2023. URL: https://doi.org/10.3390/diagnostics13122068, doi:10.3390/diagnostics13122068. This article has 22 citations.
(lakshmi2023endemicburkittlymphoma pages 1-2): Priya Saikumar Lakshmi, Cliff I Oduor, Catherine S Forconi, Viriato M’Bana, Courtney Bly, Rachel M Gerstein, Juliana A Otieno, John M Ong’echa, Christian Münz, Micah A Luftig, Michael A Brehm, Jeffrey A Bailey, and Ann M Moormann. Endemic burkitt lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies. Life Science Alliance, 6:e202101355, Mar 2023. URL: https://doi.org/10.26508/lsa.202101355, doi:10.26508/lsa.202101355. This article has 11 citations and is from a peer-reviewed journal.
(alkhreisat2023worldwideprevalenceof pages 2-3): Mutaz Jamal Al-Khreisat, Nor Hayati Ismail, Abedelmalek Tabnjh, Faezahtul Arbaeyah Hussain, Abdul Aziz Mohamed Yusoff, Muhammad Farid Johan, and Md Asiful Islam. Worldwide prevalence of epstein–barr virus in patients with burkitt lymphoma: a systematic review and meta-analysis. Diagnostics, 13:2068, Jun 2023. URL: https://doi.org/10.3390/diagnostics13122068, doi:10.3390/diagnostics13122068. This article has 22 citations.
(siddiqui2023fromthearchives pages 3-4): Saima Haleem Siddiqui, Beenu Thakral, FNU Aakash, Chi Young Ok, Zhenya Tang, and L. Jeffrey Medeiros. From the archives of md anderson cancer center: sporadic burkitt lymphoma with a complex karyotype and sox11 expression. Annals of Diagnostic Pathology, 66:152182, Oct 2023. URL: https://doi.org/10.1016/j.anndiagpath.2023.152182, doi:10.1016/j.anndiagpath.2023.152182. This article has 6 citations and is from a peer-reviewed journal.
(malfona2024refractoryburkittlymphoma pages 1-2): Francesco Malfona, Anna Maria Testi, Sabina Chiaretti, and Maria Luisa Moleti. Refractory burkitt lymphoma: diagnosis and interventional strategies. Blood and Lymphatic Cancer: Targets and Therapy, 14:1-15, Mar 2024. URL: https://doi.org/10.2147/blctt.s407804, doi:10.2147/blctt.s407804. This article has 19 citations.
(mburu2023incidenceofburkitt pages 3-5): Waruiru Mburu, Susan S. Devesa, David Check, Meredith S. Shiels, and Sam M. Mbulaiteye. Incidence of burkitt lymphoma in the united states during 2000 to 2019. International Journal of Cancer, 153:1182-1191, Jun 2023. URL: https://doi.org/10.1002/ijc.34618, doi:10.1002/ijc.34618. This article has 18 citations and is from a domain leading peer-reviewed journal.
(chamba2023clinicalapplicationof pages 1-2): Clara Chamba, Sam M. Mbulaiteye, Emmanuel Balandya, and Anna Schuh. Clinical application of circulating cell-free lymphoma dna for fast and precise diagnosis of burkitt lymphoma: precision medicine for sub-saharan africa. Cambridge Prisms: Precision Medicine, Jan 2023. URL: https://doi.org/10.1017/pcm.2023.1, doi:10.1017/pcm.2023.1. This article has 15 citations.
(coupland2024thefifthedition pages 12-12): Sarah E Coupland, Ming‐Qing Du, Judith A Ferry, Daphne de Jong, Joseph D Khoury, Lorenzo Leoncini, Kikkeri N Naresh, German Ott, Reiner Siebert, and Luc Xerri. The fifth edition of the who classification of mature b‐cell neoplasms: open questions for research. The Journal of Pathology, 262:255-270, Jan 2024. URL: https://doi.org/10.1002/path.6246, doi:10.1002/path.6246. This article has 23 citations.
(zanelli2024adiagnosticapproach pages 9-11): Magda Zanelli, Francesca Sanguedolce, Maurizio Zizzo, Stefano Ricci, Alessandra Bisagni, Andrea Palicelli, Valentina Fragliasso, Benedetta Donati, Giuseppe Broggi, Ioannis Boutas, Nektarios Koufopoulos, Moira Foroni, Francesca Coppa, Andrea Morini, Paola Parente, Valeria Zuccalà, Rosario Caltabiano, Massimiliano Fabozzi, Luca Cimino, Antonino Neri, and Stefano Ascani. A diagnostic approach in large b-cell lymphomas according to the fifth world health organization and international consensus classifications and a practical algorithm in routine practice. International Journal of Molecular Sciences, 25:13213, Dec 2024. URL: https://doi.org/10.3390/ijms252313213, doi:10.3390/ijms252313213. This article has 10 citations.
(crombie2021thetreatmentof pages 1-2): Jennifer Crombie and Ann LaCasce. The treatment of burkitt lymphoma in adults. Blood, 137:743-750, Feb 2021. URL: https://doi.org/10.1182/blood.2019004099, doi:10.1182/blood.2019004099. This article has 160 citations and is from a highest quality peer-reviewed journal.
(chamba2023clinicalapplicationof pages 2-3): Clara Chamba, Sam M. Mbulaiteye, Emmanuel Balandya, and Anna Schuh. Clinical application of circulating cell-free lymphoma dna for fast and precise diagnosis of burkitt lymphoma: precision medicine for sub-saharan africa. Cambridge Prisms: Precision Medicine, Jan 2023. URL: https://doi.org/10.1017/pcm.2023.1, doi:10.1017/pcm.2023.1. This article has 15 citations.
(harlendea2024ki67asa pages 2-4): Nicyela J Harlendea and Kent Harlendo. Ki-67 as a marker to differentiate burkitt lymphoma and diffuse large b-cell lymphoma: a literature review. Cureus, Oct 2024. URL: https://doi.org/10.7759/cureus.72190, doi:10.7759/cureus.72190. This article has 11 citations.
(tandon2023translocationtalesunraveling pages 16-17): Amol Tandon, Jissy Akkarapattiakal Kuriappan, and Vaibhav Dubey. Translocation tales: unraveling the myc deregulation in burkitt lymphoma for innovative therapeutic strategies. Lymphatics, 1:97-117, Jul 2023. URL: https://doi.org/10.3390/lymphatics1020010, doi:10.3390/lymphatics1020010. This article has 6 citations.
(lakshmi2023endemicburkittlymphoma pages 10-12): Priya Saikumar Lakshmi, Cliff I Oduor, Catherine S Forconi, Viriato M’Bana, Courtney Bly, Rachel M Gerstein, Juliana A Otieno, John M Ong’echa, Christian Münz, Micah A Luftig, Michael A Brehm, Jeffrey A Bailey, and Ann M Moormann. Endemic burkitt lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies. Life Science Alliance, 6:e202101355, Mar 2023. URL: https://doi.org/10.26508/lsa.202101355, doi:10.26508/lsa.202101355. This article has 11 citations and is from a peer-reviewed journal.
(chamba2023clinicalapplicationof pages 3-4): Clara Chamba, Sam M. Mbulaiteye, Emmanuel Balandya, and Anna Schuh. Clinical application of circulating cell-free lymphoma dna for fast and precise diagnosis of burkitt lymphoma: precision medicine for sub-saharan africa. Cambridge Prisms: Precision Medicine, Jan 2023. URL: https://doi.org/10.1017/pcm.2023.1, doi:10.1017/pcm.2023.1. This article has 15 citations.
(chamba2023clinicalapplicationof pages 4-5): Clara Chamba, Sam M. Mbulaiteye, Emmanuel Balandya, and Anna Schuh. Clinical application of circulating cell-free lymphoma dna for fast and precise diagnosis of burkitt lymphoma: precision medicine for sub-saharan africa. Cambridge Prisms: Precision Medicine, Jan 2023. URL: https://doi.org/10.1017/pcm.2023.1, doi:10.1017/pcm.2023.1. This article has 15 citations.